Comparative analysis of the transparency committee opinions concerning the added medical benefit levels depending on the therapeutic areas: distribution of innovation and trend assessment for 2016-2021
"In France, for each indication of a drug that has a positive reimbursement decision (suffi cient medical benefi t), the Transparency Committee (TC) of the HAS..."
Innovation Value Framework Evidence from EU-4 and UK
"The assessment of health technologies is a key tool used in the decision-making process in health policies. The innovation assessment and clinical benefit is a complex discipline for which different methodologies are adopted at the national level..."